Zimmer Biomet (ZBH) is well-poised to grow in the coming quarters owing to the encouraging business recovery and increased provider capacity driving backlog pull-through. The company also progresses on the four-pillar strategy to expand the Knee business. Further, the global musculoskeletal market’s gradual stabilization bodes well for its operations. Meanwhile, unfavorable solvency and currency fluctuations raise concerns for Zimmer Biomet. In the past year, this Zacks Rank #3 (Hold) stock has declined 11% ...

WARSAW, Ind., May 13, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the second quarter of 2024. The cash dividend of $0.24 per share is payable on or about July 31, 2024 to stockholders of record as of the close of business on June 26, 2024. About Zimmer Biomet Zimmer Biomet is a global medical technology leader with a comprehensiv ...

As detailed in the report, Zimmer Biomet is committed to being a good corporate citizen and a leader in responsible, ethical business practices. Key highlights include: Achieving the highest ever employee engagement levels since our 2015 merger. Our company-wide engagement index score increased a remarkable 7 points over 2022 results, with improved scores for 100% of the indicators. Furthering our commitment to integrating health equity into our business strategy. Our new Community Centered Care (C3) framew ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2024 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 13-4151777 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 345 East Main Street, Warsaw, IN 46580 (Address of principal e ...

财务数据和关键指标变化 - 第一季度收入增长4.4%,剔除汇率影响后增长超过6% [14][47] - 调整后毛利率为72.9%,与上年持平 [53] - 调整后营业利润率为28.6%,较上年有所提升 [54] - 调整后每股收益为1.94美元,较上年1.89美元有所增长 [53] - 经营活动现金流228百万美元,自由现金流91百万美元 [58] 各条业务线数据和关键指标变化 - 膝关节业务增长4.3%,其中美国增长2.2%,国际增长7.3% [48] - 髋关节业务增长1.5%,美国增长1%,国际增长2% [49] - 软组织和骨科外科(S.E.T.)业务增长5.3%,主要得益于CMFT、上肢和运动医疗等重点领域 [50] - 其他业务增长12.2%,主要由于ROSA销售强劲 [51] 各个市场数据和关键指标变化 - 美国市场增长3.7% [48] - 国际市场增长5.4% [48] - 欧洲、中东和非洲(EMEA)地区增长强于预期 [48] 公司战略和发展方向及行业竞争 - 公司将继续专注于三大战略重点:人才和文化、卓越运营、创新和多元化 [24][26][32] - 在人才和文化方面,公司的员工敬业度和流失率保持行业领先水平 [27] - 在卓越运营方面,公司正在实施库存管理改善计划,并优化新产品上市流程 [29][30] - 在创新和多元化方面,公司管线规模已是2018年末的两倍,80%以上产品位于高于4%增长的市场 [32][33][35] - 公司将继续通过小型并购和中型并购来提升加权平均市场增长率 [37][38] 管理层对经营环境和未来前景的评论 - 公司对2024年5%-6%的收入增长目标和100-200个基点的市场份额提升目标充满信心 [39][49] - 管理层认为,新产品推出、定价改善和商业执行力将是推动2024年业绩的关键驱动因素 [19][20][21][22][23] - 公司有望在2024年实现中高单位数的调整后每股收益增长,并且自由现金流增长将超过收益增长 [16][17] 问答环节重要的提问和回答 问题1 **Travis Steed 提问** 公司的5%-6%收入增长、利润率提升和低双位数每股收益增长的算法是否为基本情况还是最佳情况?公司在正常市场环境下的可持续增长率是多少? [70][71] **Ivan Tornos 和 Suky Upadhyay 回答** - 这一算法并非仅针对2024年,而是公司的长期承诺 [71][72] - 收入增长的主要驱动因素包括新产品推出、定价改善和商业执行力 [71][72] - 利润率提升将通过多个方面实现,包括收入增长带来的固定成本摊薄、成本优化、资本配置改善等 [72][73][74] - 公司有信心在正常市场环境下实现低双位数的每股收益增长 [73] 问题2 **Vik Chopra 提问** 公司在即将到来的投资者日上会提供哪些具体的财务目标?是否会给出相对于市场的增长目标,如超过100-200个基点? [102][103] **Ivan Tornos 回答** - 公司将在投资者日上详细阐述实现财务目标的驱动因素,包括新产品推出、定价策略等 [103] - 公司的目标是实现高于市场4-5个百分点的加权平均市场增长率,具体时间线将在投资者日公布 [206] 问题3 **Chris Pasquale 提问** 第一季度公司的髋关节和膝关节业务增长略低于市场,但您提到新产品将在下半年带来加速增长。您是否仍然保持原有的2024年目标配方? [191][192] **Ivan Tornos 回答** - 公司认为第一季度的表现并未低于市场,而是与市场持平 [192][193] - 新产品推出、商业执行力以及欧洲新产品引入等将是实现5%-6%收入增长的关键 [193][194][195] - 公司对实现2024年目标充满信心 [195]

Zimmer Biomet Holdings, Inc. (ZBH) posted first-quarter 2024 adjusted earnings per share (EPS) of $1.94, exceeding the Zacks Consensus Estimate by 3.7%. The adjusted figure increased 2.6% year over year. The quarter’s adjustments included certain amortization, restructuring and other cost reduction initiatives and European Union Medical Device Regulation-related charges, among others. On a reported basis, the company registered earnings of 84 cents per share, which reflected a 24.3% decline from the year-ag ...

For the quarter ended March 2024, Zimmer Biomet (ZBH) reported revenue of $1.89 billion, up 3.2% over the same period last year. EPS came in at $1.94, compared to $1.89 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.87 billion, representing a surprise of +1.16%. The company delivered an EPS surprise of +3.74%, with the consensus EPS estimate being $1.87. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.94 per share, beating the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $1.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.74%. A quarter ago, it was expected that this orthopedic device maker would post earnings of $2.15 per share when it actually produced earnings of $2.20, delivering a surprise of 2.33%. Over the last four quarters, ...

345 E. Main St. Warsaw, IN 46580 www.zimmerbiomet.com Exhibit 99.1 Media Investors Heather Zoumas-Lubeski Zach Weiner (445) 248-0577 (908) 591-6955 heather.zoumaslubeski@zimmerbiomet.com zach.weiner@zimmerbiomet.com Zimmer Biomet Announces First Quarter 2024 Financial Results • First quarter net sales of $1.889 billion increased 3.2% and 4.4% on a constant currency1 basis • First quarter diluted earnings per share were $0.84; adjusted1 diluted earnings per share were $1.94 • Company reiterates full-year 202 ...

In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.88 per share, reflecting a decline of 0.5% compared to the same period last year. Revenues are forecasted to be $1.87 billion, representing a year-over-year increase of 2.2%. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during t ...